These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11841434)

  • 1. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes.
    Stasi R; Amadori S
    Br J Haematol; 2002 Feb; 116(2):334-7. PubMed ID: 11841434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes.
    Boula A; Voulgarelis M; Giannouli S; Katrinakis G; Psyllaki M; Pontikoglou C; Markidou F; Eliopoulos GD; Papadaki HA
    Clin Cancer Res; 2006 May; 12(10):3099-108. PubMed ID: 16707608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Abnormal polarization of T lymphocyte induces negative hematopoietic regulation in myelodysplastic syndromes].
    Wu LY; Li X; Chang CK; Ying SX; Pu Q
    Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):549-54. PubMed ID: 18078133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inhibition of hematopoiesis by sera from patients with myelodysplastic syndromes].
    Ding R; Liu H; Xu R
    Zhonghua Xue Ye Xue Za Zhi; 1999 Oct; 20(10):515-7. PubMed ID: 11721395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome.
    Wu L; Li X; Chang C; Ying S; He Q; Pu Q
    Int J Lab Hematol; 2008 Oct; 30(5):390-9. PubMed ID: 19046314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes.
    Stasi R; Amadori S; Newland AC; Provan D
    Leuk Lymphoma; 2005 Apr; 46(4):509-16. PubMed ID: 16019478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of TNF-alpha activity in tumor PC cells using anti-CD45 and anti-CD95 monoclonal antibodies.
    Jurisić V; Bogdanovic G; Srdic T; Jakimov D; Mrdjanovic J; Baltic M; Baltic VV
    Cancer Lett; 2004 Oct; 214(1):55-61. PubMed ID: 15331173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [[The role of TNF-alpha in myelodysplastic syndrome: immunoserologic and immunohistochemical studies] ].
    Molnár L; Berki T; Hussain A; Németh P; Losonczy H
    Orv Hetil; 2000 Aug; 141(33):1807-11. PubMed ID: 10979309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes.
    Katsoulidis E; Li Y; Yoon P; Sassano A; Altman J; Kannan-Thulasiraman P; Balasubramanian L; Parmar S; Varga J; Tallman MS; Verma A; Platanias LC
    Cancer Res; 2005 Oct; 65(19):9029-37. PubMed ID: 16204077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes.
    Maratheftis CI; Andreakos E; Moutsopoulos HM; Voulgarelis M
    Clin Cancer Res; 2007 Feb; 13(4):1154-60. PubMed ID: 17317824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
    Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of infliximab in active SLE: a pilot study.
    Uppal SS; Hayat SJ; Raghupathy R
    Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab.
    Toubi E; Kessel A; Mahmudov Z; Hallas K; Rozenbaum M; Rosner I
    Ann N Y Acad Sci; 2005 Jun; 1051():506-14. PubMed ID: 16126991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica.
    Karppinen J; Korhonen T; Malmivaara A; Paimela L; Kyllönen E; Lindgren KA; Rantanen P; Tervonen O; Niinimäki J; Seitsalo S; Hurri H
    Spine (Phila Pa 1976); 2003 Apr; 28(8):750-3; discussion 753-4. PubMed ID: 12698115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
    List AF
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.